Yamamura Y, Virella G, Haskill J S
Int J Cancer. 1977 May 15;19(5):707-16. doi: 10.1002/ijc.2910190517.
DBA/2 mice bearing a syngeneic mammary adenocarcioma T1699 produced high levels of tumor-specific antibody, detected by indirect immunofluorescence and subsequently identified as the IgG2a subclass. Tumor-bearer sera passively administered to normal recipients protected the animals from subsequent challenge with T1699 tumor cells butnot from challenge with a non-cross-reacting syngeneic tumor, SaD2 fibrosarcoma. Administration of sera prior to tumor challenge was found to be more effective than treatment after the challenge. The protective effect of sera appeared to parallel both antibody titers and appearance of concomitant immunity; however, sera absorbed with T1699 cells, with the indirect fluorescent antibody titers reduced more than 100-fold, conferred an almost identical level of protection. Immune suppression of serum recipients before serum transfer abolished the effect, suggesting that protection depended on a cellular immune response by the host in addition to the possible protective effect(s) of humoral antibody.
携带同基因乳腺腺癌T1699的DBA/2小鼠产生了高水平的肿瘤特异性抗体,通过间接免疫荧光检测到,随后鉴定为IgG2a亚类。将荷瘤小鼠血清被动给予正常受体,可保护动物免受随后T1699肿瘤细胞的攻击,但不能保护其免受非交叉反应同基因肿瘤SaD2纤维肉瘤的攻击。发现在肿瘤攻击前给予血清比攻击后治疗更有效。血清的保护作用似乎与抗体滴度和伴随免疫的出现平行;然而,用T1699细胞吸收的血清,间接荧光抗体滴度降低了100倍以上,却赋予了几乎相同水平的保护作用。在血清转移前对血清受体进行免疫抑制消除了这种作用,这表明除了体液抗体可能的保护作用外,保护作用还依赖于宿主的细胞免疫反应。